Clinical Trial Update: PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a PD-1 monoclonal antibody in combination with gemcitabine and cisplatin, followed by selective radiotherapy, for unresectab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• PD-1 monoclonal antibody

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 2 | Status: NOT_YET_RECRUITING